Zydus gets U.S. FDA tentative nod for Rifaximin tablets 550 mg 

Generic drug manufacturers Zydus Lifescienes have received temporary approval for Rifaximin Tablet, 550 mg from US Food and Drug Administration (FDA). The product is indicated to the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Rifaximine’s annual sales in the United States were $ 2672.9 million, stating that the March 2025 cited the number of March 2025. The production of the product will be done at the group’s manufacturing site in SEZ II, Ahmedabad, it said on Monday.